iTeos Therapeutics Past Earnings Performance
Past criteria checks 0/6
iTeos Therapeutics has been growing earnings at an average annual rate of 3%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been declining at an average rate of 21.4% per year.
Key information
3.0%
Earnings growth rate
98.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -21.4% |
Return on equity | -25.0% |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 25iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Jan 10Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%
May 13Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding
Mar 21The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically
Aug 12iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04
Aug 10iTeos Therapeutics: Too Many Unknowns
Jul 27News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts
May 11Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic
Nov 25We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth
Aug 24iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share
Aug 15GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler
Jun 15We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth
Feb 07Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?
Dec 16iTeos Therapeutics EPS misses by $0.11
Nov 12Revenue & Expenses Breakdown
How iTeos Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -135 | 51 | 118 |
31 Dec 23 | 13 | -113 | 50 | 110 |
30 Sep 23 | 67 | -62 | 49 | 109 |
30 Jun 23 | 86 | -28 | 47 | 103 |
31 Mar 23 | 128 | 12 | 45 | 101 |
31 Dec 22 | 268 | 97 | 44 | 96 |
30 Sep 22 | 454 | 261 | 42 | 89 |
30 Jun 22 | 539 | 330 | 40 | 81 |
31 Mar 22 | 497 | 298 | 44 | 69 |
31 Dec 21 | 345 | 215 | 41 | 59 |
30 Sep 21 | 104 | 15 | 37 | 51 |
30 Jun 21 | 0 | -67 | 33 | 44 |
31 Mar 21 | 0 | -50 | 20 | 36 |
31 Dec 20 | 0 | -43 | 15 | 30 |
30 Sep 20 | 0 | -35 | 12 | 26 |
30 Jun 20 | 0 | -31 | 10 | 22 |
31 Mar 20 | 0 | -28 | 9 | 20 |
31 Dec 19 | 0 | -27 | 9 | 18 |
Quality Earnings: ITOS is currently unprofitable.
Growing Profit Margin: ITOS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ITOS is unprofitable, but has reduced losses over the past 5 years at a rate of 3% per year.
Accelerating Growth: Unable to compare ITOS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ITOS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: ITOS has a negative Return on Equity (-25%), as it is currently unprofitable.